Previous 10 | Next 10 |
home / stock / konef / konef news
KGK has received approval from Health Canada for Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), a...
The Research License greatly reduces the timelines required for conducting cannabis research as it eliminates the need for obtaining a project specific cannabis research license Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: ...
A randomized, triple-blind, placebo-controlled clinical trial involving supplementation with a bioflavonoid ingredient UP446 provides evidence for a robust, healthy immune response in healthy adults following influenza vaccination. Wellbeing Digital Sciences Inc. (“ Wellbeing...
KGK has submitted a clinical trial application for Phase IIa clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 )...
Clinic reaches patient milestone in less than two years since being acquired by Wellbeing Digital Sciences Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidenc...
Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, includin...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...
KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based men...
Gefion Canada GT4 technology was used to deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (N...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...
News, Short Squeeze, Breakout and More Instantly...
KetamineOne Capital Limited Company Name:
KONEF Stock Symbol:
OTCMKTS Market:
KetamineOne Capital Limited Website:
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...
Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) ( NEO: MEDI ) ( OTC: KONEF ) ( FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psych...
Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedel...